Valneva says early studies show COVID-19 vaccine effective against Omicron – Reuters

Valneva says early studies show COVID-19 vaccine effective against Omicron – Reuters

Jan 19 (Reuters) - French biotech firm Valneva (VLS.PA) said on Wednesday that preliminary studies showed that three doses of its inactivated COVID-19 vaccine candidate neutralised the Omicron variant of the disease.

All of the serum samples tested presented neutralizing antibodies against the ancestral virus and Delta variant, it said, while 87% of samples did so against the Omicron variant.

"We are extremely pleased with these results," said Chief Medical Officer Juan Carlos Jaramillo in a statement, noting that these added to an earlier Phase III trial that showed improved immune response with two doses of the VLA2001 candidate.